Oryzon Genomics S.A. (BME:ORY)
Spain · Delayed Price · Currency is EUR 3.410
+0.090 (2.71%)
Oct 28, 2025, 5:38 PM CET
Oryzon Genomics Company Description
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders.
Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases.
Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases.
The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Oryzon Genomics S.A.
| Country | Spain |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 47 |
| CEO | Carlos Manuel Arjol |
Contact Details
Address: Sant Ferran 74 Cornellà de Llobregat, 08940 Spain | |
| Phone | 34 93 515 13 13 |
| Website | oryzon.com |
Stock Details
| Ticker Symbol | ORY |
| Exchange | Madrid Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | ES0167733015 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carlos Manuel Buesa Arjol | Co-Founder, Chairman, Chief Executive Officer and President |
| Enric Rello Condomines | Chief Operating Officer and Chief Financial Officer |
| Jordi Xaus Pey | Scientific Director |
| Xavier Perpinya Ribera | Head of Internal Audit and Compliance |
| Augusto Pinel Rubio | Secretary |
| Emili Torrell Cortada | Director of Business Development |
| Neus Virgili Bernado | Director of Industrial Property |
| Dr. Michael Thomas Ropacki Ph.D. | Medical Director of SNC |
| Sonia Paloma Gutierrez Bezon | Director of Clinical Operations |